SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+32.15%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$901M
AUM Growth
+$901M
(-9.2%)
Cap. Flow
-$248M
Cap. Flow
% of AUM
-27.47%
Top 10 Holdings %
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
33
Top Buys
| 1 |
HCA Healthcare
HCA
|
$27.5M |
| 2 |
IDEAYA Biosciences
IDYA
|
$20.1M |
| 3 |
Penumbra
PEN
|
$20M |
| 4 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$18.4M |
| 5 |
GSK
GSK
|
$12.4M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$38.2M |
| 2 |
Arcellx
ACLX
|
$26.9M |
| 3 |
Insulet
PODD
|
$20.4M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$20.3M |
| 5 |
Evolus
EOLS
|
$19M |
Sector Composition
| 1 | Healthcare | 99.95% |
| 2 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Xenon Pharmaceuticals
XENE
$2.99B
| $2.67M | 0.3% |
58,000
+6,000
| +12% | +$276K |
|
52
Hologic
HOLX
$14.7B
| $2.43M | 0.27% |
+34,000
| New | +$2.43M |
|
53
Annexon
ANNX
$225M
| $2.34M | 0.26% |
515,400
| – | – |
|
54
AbbVie
ABBV
$374B
| $2.29M | 0.25% |
+14,800
| New | +$2.29M |
|
55
Protagonist Therapeutics
PTGX
$3.62B
| $1.9M | 0.21% |
+83,000
| New | +$1.9M |
|
|
BCYC
56
Bicycle Therapeutics
BCYC
$492M
| $1.72M | 0.19% |
95,000
-296,800
| -76% | -$5.37M |
|
57
VYNE Therapeutics
VYNE
$8.09M
| $1.64M | 0.18% |
+703,868
| New | +$1.64M |
|
58
Applied Therapeutics
APLT
$73.7M
| $1.54M | 0.17% |
460,793
-731,833
| -61% | -$2.45M |
|
59
Nurix Therapeutics
NRIX
$723M
| $1.48M | 0.16% |
143,000
-671,000
| -82% | -$6.92M |
|
60
Y-mAbs Therapeutics
YMAB
$390M
| $1.07M | 0.12% |
157,182
| – | – |
|
61
Avita Medical
RCEL
$116M
| $1.03M | 0.11% |
75,000
| – | – |
|
62
Apogee Therapeutics
APGE
$2.27B
| $978K | 0.11% |
35,000
| – | – |
|
63
4D Molecular Therapeutics
FDMT
$287M
| $927K | 0.1% |
45,748
-78,000
| -63% | -$1.58M |
|
64
Illumina
ILMN
$15.2B
| $738K | 0.08% |
+5,448
| New | +$738K |
|
|
INBX
65
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $570K | 0.06% |
15,000
-534,183
| -97% | -$20.3M |
|
66
Castle Biosciences
CSTL
$673M
| $561K | 0.06% |
26,000
-257,500
| -91% | -$5.56M |
|
67
The Beauty Health Co
SKIN
$254M
| $482K | 0.05% |
155,000
-2,651,720
| -94% | -$8.25M |
|
68
Immunic
IMUX
$79.4M
| $450K | 0.05% |
300,000
| – | – |
|
|
IMGN
69
DELISTED
Immunogen Inc
IMGN
| $387K | 0.04% |
+13,050
| New | +$387K |
|
70
Adverum Biotechnologies
ADVM
$68.2M
| $320K | 0.04% |
+42,500
| New | +$320K |
|
71
GeneDx Holdings
WGS
$3.65B
| $165K | 0.02% |
60,000
-721,396
| -92% | -$1.98M |
|
72
Xeris Biopharma Holdings
XERS
$1.27B
| $146K | 0.02% |
62,083
-242,000
| -80% | -$569K |
|
73
Liquidia Corp
LQDA
$2.52B
| $120K | 0.01% |
10,000
-165,000
| -94% | -$1.98M |
|
74
BioLife Solutions
BLFS
$1.2B
| – | – |
-439,000
| Closed | -$6.06M |
|
75
Design Therapeutics
DSGN
$339M
| – | – |
-1,025,000
| Closed | -$2.42M |
|